scholarly journals O17.4 First clinical evaluation of a 30-minute point-of-care-test for Chlamydia trachomatis and Neisseria gonorrhoeae infection in UK sexual health clinics

2021 ◽  
Author(s):  
S Fuller ◽  
M Furegato ◽  
L Phillips ◽  
E Harding-Esch ◽  
A Pacho ◽  
...  
Keyword(s):  
Chlamydia Trachomatis ◽  
Neisseria Gonorrhoeae ◽  
Sexual Health ◽  
Clinical Evaluation ◽  
Point Of Care ◽  
Point Of Care Test ◽  
Health Clinics ◽  
Minute Point ◽  
Sexual Health Clinics

Prevalence and predictors of chlamydia co-infection among patients infected with gonorrhoea at a sexual health clinic in Sydney

Sexual Health ◽  
2012 ◽  
Vol 9 (4) ◽  
pp. 392 ◽  
Author(s):  
David J. Templeton ◽  
Niveditha Manokaran ◽  
Catherine C. O'Connor
Keyword(s):  
Chlamydia Trachomatis ◽  
Confidence Interval ◽  
Neisseria Gonorrhoeae ◽  
Sexual Health ◽  
Medical Records ◽  
Clinic Visit ◽  
Health Clinic ◽  
Gram Stain ◽  
Health Clinics ◽  
Sexual Health Clinics

Anogenital gonorrhoea (Neisseria gonorrhoeae) is commonly diagnosed at sexual health clinics by on-site microscopy. Whether to add anti-chlamydial therapy in such situations is unclear. The medical records of all patients diagnosed with gonorrhoea between May 2005 and April 2010 at RPA Sexual Health were reviewed. Of 165 patients with anogenital gonorrhoea, 27 (16.4%, 95% confidence interval (CI) 11.1–22.9%) were co-infected with chlamydia (Chlamydia trachomatis). Compared with those only infected with anogenital gonorrhoea, there was no correlation of anogenital gonorrhoea–chlamydia co-infection with any demographic, behavioural or clinical variables examined. Anti-chlamydial therapy should be considered for all patients with gram stain diagnosed anogenital gonorrhoea at the initial clinic visit.

Diagnostic tests for detecting Chlamydia trachomatis and Neisseria gonorrhoeae in rectal and pharyngeal specimens

2021 ◽  
Author(s):  
Paul C. Adamson ◽  
Jeffrey D. Klausner
Keyword(s):  
Chlamydia Trachomatis ◽  
Neisseria Gonorrhoeae ◽  
Bacterial Infections ◽  
Point Of Care ◽  
High Sensitivity ◽  
Population Level ◽  
The United States ◽  
Nucleic Acid Amplification ◽  
Point Of Care Test ◽  
Control And Prevention

Chlamydia trachomatis and Neisseria gonorrhoeae are two of the most often reported bacterial infections in the United States. The rectum and oropharynx are important anatomic sites of infection and can contribute to ongoing transmission. Nucleic acid amplification tests (NAATs) are the mainstays for the detection of C. trachomatis and N. gonorrhoeae infections owing to their high sensitivity and specificity. Several NAATs have been evaluated for testing in rectal and pharyngeal infections. A few assays recently received clearance by the Food and Drug Administration, including one point-of-care test. Those assays can be used for testing in symptomatic individuals, as well as for asymptomatic screening in certain patient populations. Routine screening for C. trachomatis in pharyngeal specimens is not recommended by the Centers for Disease Control and Prevention, though is often performed due to the use of multiplex assays. While expanding the types of settings for screening and using self-collected rectal and pharyngeal specimens can help to increase access and uptake of testing, additional research is needed to determine the potential benefits and costs associated with increased screening for rectal and pharyngeal C. trachomatis and N. gonorrhoeae infections on a population level.

scholarly journals 424. Use of the ResistancePlus® MG Multiplex PCR Assay to Determine the Prevalence of Mycoplasma genitalium and Macrolide Resistance in a High-Risk US Population

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S213-S213
Author(s):  
Charles Cartwright ◽  
Ayla Harris ◽  
Michael Levandoski ◽  
Amanda Pherson ◽  
Melinda Nye
Keyword(s):  
Neisseria Gonorrhoeae ◽  
Sexual Health ◽  
Mycoplasma Genitalium ◽  
Macrolide Resistance ◽  
Nucleic Acid Amplification ◽  
Pcr Assay ◽  
Health Clinics ◽  
Multiplex Pcr Assay ◽  
Therapeutic Decisions ◽  
Sexual Health Clinics

Abstract Background Mycoplasma genitalium is a significant agent of sexually transmitted infection (STI). Cure rates have declined as rates of macrolide resistance has become increasingly prevalent. Diagnosis of M. genitalium infection and macrolide resistance detection is possible using nucleic-acid amplification tests (NAAT); use of such assays could improve patient management and antimicrobial stewardship. In this study we used one such assay, ResistancePlus MG (RPMG) to determine the prevalence of M. genitalium infection and macrolide resistance in a cohort of patients attending 3 public sexual health clinics in mid-Atlantic US states. Methods De-identified urogenital samples submitted to the LabCorp facility in Burlington, NC for routine Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) NAAT testing from 3 public sexual health clinics were analyzed in the study. All samples had been collected in the Aptima Specimen Collection system and tested with the Aptima Combo 2 CT/NG NAAT. A total of 1,261 samples (770 male, 491 female) from this cohort were successfully tested for M. genitalium and macrolide-resistance mediating mutations (MRMM) using the RPMG multiplexed PCR assay. Results The prevalence of M. genitalium in this patient cohort was 10.4% (131/1,261), not significantly different to the prevalence of C. trachomatis (12.0%; P = 0.202) but significantly higher than the prevalence of Neisseria gonorrhoeae (6.7%; P = 0.0009). Sixty of the 131 M. genitalium positives were also positive for MRMM and thus azithromycin resistant. Conclusion M. genitalium infections were common amongst unselected individuals evaluated for treatable STI in the eastern United States and the rate of macrolide resistance in this population was significant. In addition, the RPMG assay was shown to be a simple and accurate method for simultaneously diagnosing M. genitalium infections and detecting MRMM and could be used to inform therapeutic decisions. Disclosures All authors: No reported disclosures.

Detection of Neisseria gonorrhoeae and Chlamydia trachomatis from pooled rectal, pharyngeal and urine specimens in men who have sex with men

2017 ◽  
Vol 94 (4) ◽  
pp. 293-297 ◽  
Author(s):  
David John Speers ◽  
I-Ly Joanna Chua ◽  
Justin Manuel ◽  
Lewis Marshall
Keyword(s):  
Nucleic Acid ◽  
Chlamydia Trachomatis ◽  
Neisseria Gonorrhoeae ◽  
Sexual Health ◽  
Point Of Care ◽  
Standard Of Care ◽  
Urine Samples ◽  
Health Clinic ◽  
Sex With Men ◽  
The Cost

ObjectivesScreening of men who have sex with men (MSM) for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) requires sampling from anorectal and pharyngeal sites in addition to urogenital sampling. Due to the cost of testing multiple anatomical sites individually testing of pooled specimens has potential merit. The Cepheid GeneXpert CT/NG assay (GeneXpert), which also has potential for point-of-care nucleic acid testing in the sexual health clinic, has not been assessed for pooled specimen testing.MethodsWe prospectively compared GeneXpert testing of pooled pharyngeal and rectal swabs with urine samples to standard of care testing of individual specimens from 107 participants using the Roche cobas 4800 CT/NG assay (cobas) for CT and NG in high-risk MSM attending an inner city sexual health clinic.ResultsWe found testing of pooled pharyngeal, rectal and urine samples by the GeneXpert to have 100% agreement for NG and 94% overall agreement for CT when compared with individual specimen testing by cobas. For CT testing, 14 cases were detected for both tests, 4for cobas only, 2 for GeneXpert only and 89 participants were negative for both tests.ConclusionsPooled specimen CT and NG testing by the GeneXpert was accurate when compared with single specimen testing and has potential for screening MSM for CT and NG. The role of pooled specimen testing with the GeneXpert as a point-of-care nucleic acid test in MSM requires further investigation.

Should we change the focus of health promotion in sexual health clinics?

Sexual Health ◽  
2010 ◽  
Vol 7 (4) ◽  
pp. 407 ◽  
Author(s):  
Rudiger Pittrof ◽  
Elizabeth Goodburn
Keyword(s):  
Risk Factors ◽  
Health Promotion ◽  
Cost Effectiveness ◽  
Reproductive Health ◽  
Sexual Health ◽  
Sexual And Reproductive Health ◽  
Health Clinics ◽  
Unknown Risk ◽  
Sexual Health Clinics ◽  
The Cost

The effectiveness of sexual behaviour change interventions in sexual health clinics is unknown. Risk factors for poor sexual and reproductive health such as depression, violence, alcohol and smoking in sexual health clinics are all common and can be identified easily in sexual health services. Targeting these risk factors could be as effective as traditional sexual health promotion and could have additional benefits. The authors propose a pilot to assess the cost-effectiveness and acceptability of incorporating screening and interventions for these risk factors.

scholarly journals From silos to buckets: a qualitative study of how sexual health clinics address their clients’ mental health needs

2020 ◽  
Vol 111 (2) ◽  
pp. 220-228 ◽  
Author(s):  
Stéphanie Black ◽  
Travis Salway ◽  
Naomi Dove ◽  
Jean Shoveller ◽  
Mark Gilbert
Keyword(s):  
Mental Health ◽  
Qualitative Study ◽  
Sexual Health ◽  
Health Needs ◽  
Mental Health Needs ◽  
Health Clinics ◽  
Sexual Health Clinics
Sign in / Sign up

Export Citation Format

Share Document